This year our team will continue to work with Mochida Pharmaceutical Ltd. to explore further indications for alginate-based technologies, with projects focused on #tendon protection, #cavernous nerve repair and #cartilage treatment on the horizon. The product pipeline is exciting and our vision is clear – to develop #innovative medical technologies to enhance the wellbeing of patients globally. Pictured are Hitoshi Mizuno – Executive Managing Officer, Head of Biomaterials Business Division at Mochida Pharmaceutical; Gerard Insley – Chief Science Officer at PBC Biomed; Pierse Danaher -Finance Director at PBC Biomed; and Akihisa Iwabuchi – Associate Manager, Medical Device Quality Management and Regulatory Affairs at Mochida Pharmaceutical Ltd, on a recent trip to the Mochida Headquarters in Tokyo, Japan. #partnership #productpipeline #acceleratingmedicalinnovation #alginate

The wait is nearly over! Join us at the London Vet Show on November 14-15, 2024, at ExCeL London, England to discover how biomimetic technology is advancing veterinary care. 📍 Visit Booth S06 for live demos of our latest innovations: – Copperhawk: Natural Animal first aid. – OssiVet™: A breakthrough bioadhesive designed to enhance surgical outcomes. Demo Times: 🕙 10:00 | 🕦 12:30 | 🕒 15:00 (both days) – See our technology in action! Don’t miss out on how PBC BioVet is reshaping animal health through innovation. 🗓️ Dates: November 14-15, 2024 📍 Booth: S06, ExCeL London https://lnkd.in/eY8_59Mn #LondonVetShow #VeterinaryInnovation #BioMed #BioVet #Copperhawk #OssiVet #AnimalHealth

We are excited to announce the release of new publication: ‘Alginate Use in Orthopedics and Peripheral Nerve Repair: A Systematic Review’; which is now live on the Cureus website. The aim of the paper is to examine alginate’s use in orthopaedic indications, as well as look at future applications of alginate for peripheral nerve repair. This publication was written by Dr Joshua Hustedt who based out of Banner Health, in Phoenix AZ. Dr. Joshua Hustedt, MD/MHS is a double board-certified, fellowship trained, hand, upper extremity, and peripheral nerve surgeon. Dr Hustedt has worked as part of the ReFeel development team with our partner company and legal manufacturer Mochida Pharmaceutical Ltd. Full publication can be accessed below – congratulations to Dr Hustedt on its release! https://www.cureus.com/articles/302391-alginate-use-in-orthopedics-and-peripheral-nerve-repair-a-systematic-review #ReFeelnerverepairsolution #peripheralnerverepair #nerverepair #alginate #orthopaedics #acceleratingmedicalinnovation

It was fantastic to welcome the Enterprise Ireland #DTIF consortium team to our Shannon Headquarters at the start of September for a project progress meeting. Thank you to Nicholas Dunne and the DCU postgraduate team, the Dolmen Design & Innovation team, as well as Jackie FitzGerald of Enterprise Ireland for making the trip! #DTIF #disruptivetechnology #OsStic #development #researchanddevelopment #enterpriseireland #acceleratingmedicalinnovation

First image of the team at the World Biomaterials Congress in South Korea is in! Tina Hashemi is also pictured presenting on a ‘Comparative Study on the Corrosion Behaviour of Pure Mg and WE43 Alloy with Novel Dual-Layer CaP Coating for Orthopaedic Applications.’ Congratulations to Tina, Nicholas Dunne and other researchers involved in this project! I-Form, the SFI Research Centre for Advanced Manufacturing #WBC #biomaterials #acceleratingmedicalinnovation #DCU #PBCbiomed #collaborativeresearch

This week our team are South Korea-bound to speak at the World Biomaterials Congress (WBC) 2024! CSO Gerard Insley will be speaking on one of our co-development projects with Royal College of Surgeons in Ireland (RCSI) and Munster Technological University -‘Octacalcium phosphate scaffolds modification and functionalisation delivers superior bone healing in-vitro and in vivo.’ R&D Engineer Antzela Tzagiollari will be presenting on ‘Bioinspired Adhesives: Unlocking the potential of phosphoserine-modified calcium phosphates for effective bone repair and regeneration.’ This project is a collaborative effort between PBC Biomed with Dublin City University’s Medical Engineering Research Centre. Finally, Tina Hashemi a PhD researcher at DCU’s Medical Engineering Research Centre, is speaking on our co-development project with I-Form, the SFI Research Centre for Advanced Manufacturing – ‘Advancing corrosion control in biodegradable magnesium implants through dual-layer calcium phosphate coatings for enhanced bone remodeling.’ An exciting conference for our team and the innovation programmes they are driving – good luck to all three speakers! #WBC #worldbiomaterialsconference2024 #pbcbiomed #dcu

Our Chief Science Officer Gerard Insley and Chief Medical Officer Thomas A. (Toney) Russell MD, had the pleasure of visiting the University of Mississippi and the University of Memphis last week. Our Memphis base offers a fantastic opportunity for us to build partnerships with local research institutions. We are working with the University of Mississippi to explore an opportunity expand our veterinary business; while The University of Memphis offers a vast pool of research talent within the engineering space, among others. Nurturing a relationship with these institutions will be instrumental in allowing us to continue to progress our innovation programs, and subsequently drive the development of #disruptive new medical technologies for patients. Pictured below is Gerard and Dr Russell with Troy D. Drewry, Professor of Practice in Biomedical Engineering, and Operations Manager – Center for Diagnostics, Design, Devices, and Biomechanics, at the School of Engineering in OleMiss. More to come on this soon! #acceleratingmedicalinnovation #researchpartners #olemiss #universityofmississippi #universityofmemphis #researchanddevelopment #medtech

Biomimetic Innovations Ltd R&D Engineer Antzela Tzagiollari and the research team at DCU recently published a paper titled; ‘Multi-objective property optimisation of a phosphoserine-modified calcium phosphate cement for orthopaedic and dental applications using design of experiments methodology.’ This publication explains how their DoE approach successfully optimised the composition of OsStic®, demonstrating that the liquid: powder ratio (LPR) and quantity of phosphoserine (wt%) significantly influences the material’s handling, mechanical and adhesion properties. Subsequently, the DoE optimisation process identified the optimal formulation for OsStic®; demonstrating rapid setting, achieving complete solidification within 5 minutes, while also achieving high mechanical and adhesive properties (compressive strength of 29.2 ± 4.9 MPa and bond/shear strength of 3.6 ± 0.9 MPa). Additional findings highlighted the ability of OsStic® to effectively support and stabilise bone fragments during the initial stages of natural bone healing; showing that this ground-breaking new material fulfils the clinical requirements for working and setting times, static mechanical, degradation properties, and injectability. This further supports our belief that OsStic will enable surgeons to stabilise complex bone fractures; representing a significant advancement in treatment options, as well as the potential to greatly enhance patient outcomes. Read the full publication here.

Part One of our ‘Strengthening the Bond’ symposium series at the Orthopaedic Trauma Association meeting in Tampa, focused on the unanswered challenges of osteosynthesis, as well as a first look at research on a promising new bio-adhesive. This surgeon panel, consisting of Professor Peter Giannoudis, Dr Tracy Watson, Dr Thomas A Russell, Dr Hassan Mir and Dr Alicja Bojan, have now subsequently published an editorial summarising this discussion. Editorial| Volume 54, Issue 12, 111154, December 2023. Modern osteosynthesis of periarticular fractures: The role of provisional fixation revisited. Available to view here: https://www.injuryjournal.com/article/S0020-1383(23)00871-9/abstract #acceleratingmedicalinnovation #Periarticular #Provisional fixation #Osteosynthesis

Innovative new medical implants could be on the way following a deal between PBC BioMed and I-Form, the Science Foundation Ireland-backed research centre. The €300,000 four-year agreement is for a project to investigate the feasibility of manufacturing magnesium-based medical implants using state-of-the art metal 3D printing and coating processes. The aim is to demonstrate improved implant performance while developing a novel, cost- effective, advanced manufacturing process. Article by Charlie Taylor on Irish Times. Image: Prof Nicholas Dunne, who is leading the I-Form team along with Dr Tanya Levingstone at DCU